X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
idelalisib (392) 392
index medicus (235) 235
humans (183) 183
ibrutinib (179) 179
oncology (152) 152
hematology (121) 121
chronic lymphocytic leukemia (117) 117
rituximab (102) 102
chronic lymphocytic-leukemia (99) 99
leukemia, lymphocytic, chronic, b-cell - drug therapy (78) 78
open-label (75) 75
cll (70) 70
cancer (64) 64
leukemia (63) 63
venetoclax (63) 63
female (61) 61
male (61) 61
pi3k (59) 59
aged (57) 57
inhibitor (52) 52
middle aged (50) 50
lymphomas (48) 48
pharmacology & pharmacy (48) 48
antineoplastic agents - therapeutic use (47) 47
lymphoma (45) 45
treatment outcome (43) 43
animals (38) 38
adult (37) 37
hemic and lymphatic diseases (37) 37
initial therapy (37) 37
antineoplastic agents - pharmacology (36) 36
aged, 80 and over (35) 35
cal-101 (35) 35
chemotherapy (35) 35
phosphatidylinositol 3-kinases - antagonists & inhibitors (35) 35
b-cell receptor (34) 34
care and treatment (34) 34
follicular lymphoma (34) 34
survival (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
fludarabine (31) 31
ofatumumab (30) 30
previously untreated patients (30) 30
quinazolinones - therapeutic use (30) 30
therapy (30) 30
cyclophosphamide (29) 29
medicine & public health (29) 29
purines - therapeutic use (29) 29
quinazolinones - pharmacology (29) 29
chronic lymphatic leukemia (28) 28
leukemia, lymphocytic, chronic, b-cell - pathology (28) 28
pathway (28) 28
antineoplastic agents - adverse effects (27) 27
molecular targeted therapy (27) 27
obinutuzumab (27) 27
p110-delta (26) 26
prognosis (26) 26
purines - pharmacology (26) 26
apoptosis (24) 24
article (24) 24
patients (24) 24
phosphoinositide 3-kinase (24) 24
protein kinase inhibitors - therapeutic use (24) 24
signal transduction - drug effects (24) 24
chronic lymphocytic leukaemia (23) 23
purines - administration & dosage (22) 22
cell line, tumor (21) 21
protein kinase inhibitors - pharmacology (21) 21
quinazolinones - administration & dosage (21) 21
kinases (20) 20
leukemia, lymphocytic, chronic, b-cell - mortality (20) 20
phase-ii trial (20) 20
analysis (19) 19
cell biology (19) 19
class i phosphatidylinositol 3-kinases - antagonists & inhibitors (19) 19
non-hodgkin-lymphoma (19) 19
targeted therapy (19) 19
antineoplastic agents - administration & dosage (18) 18
chemistry, medicinal (18) 18
lenalidomide (18) 18
safety (18) 18
activation (17) 17
chemoimmunotherapy (17) 17
enzyme inhibitors - pharmacology (17) 17
hematology, oncology and palliative medicine (17) 17
immunotherapy (17) 17
leukemia, lymphocytic, chronic, b-cell - genetics (17) 17
lymphocytes b (17) 17
mice (17) 17
phosphatidylinositol 3-kinase (17) 17
pi3k-delta (17) 17
pyrimidines - therapeutic use (17) 17
treatment-naive (17) 17
combination (16) 16
leukemia, lymphocytic, chronic, b-cell - diagnosis (16) 16
lymphatic leukemia (16) 16
lymphoma, non-hodgkin - drug therapy (16) 16
minimal residual disease (16) 16
mutation (16) 16
recurrence (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (377) 377
French (5) 5
Spanish (5) 5
Czech (4) 4
Polish (3) 3
German (2) 2
Turkish (2) 2
Croatian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Surgical Pathology, ISSN 0147-5185, 12/2015, Volume 39, Issue 12, pp. 1653 - 1660
Journal Article
American Journal of Surgical Pathology, ISSN 0147-5185, 12/2015, Volume 39, Issue 12, pp. 1661 - 1667
Journal Article
Journal of Chemotherapy, ISSN 1120-009X, 07/2018, Volume 30, Issue 5, pp. 318 - 322
Idelalisib is a potent and selective inhibitor of the PI3Kδ approved since September 2014 for the treatment of several types of B cell malignancies. Pulmonary... 
Idelalisib-related pneumonitis | idelalisib-associated pneumonitis | idelalisib | INFECTIOUS DISEASES | CLL | MANAGEMENT | ONCOLOGY | RITUXIMAB | PNEUMONITIS | PHARMACOLOGY & PHARMACY | PHASE-2
Journal Article
by Cheng, S and Guo, A and Lu, P and Ma, J and Coleman, M and Wang, YL
LEUKEMIA, ISSN 0887-6924, 04/2015, Volume 29, Issue 4, pp. 895 - 900
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has produced remarkable clinical response in chronic lymphocytic leukemia (CLL) and mantle cell... 
BCR | EARLY EVENTS | SYK | ONCOLOGY | IDELALISIB | TYROSINE KINASE | BTK | PROLIFERATION | HEMATOLOGY
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 11, pp. 932 - 932
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 10/2015, Volume 56, Issue 10, pp. 2779 - 2786
Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood... 
phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor | transaminitis | colitis | pneumonitis | Idelalisib | diarrhea | Idelalisib, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor | phosphatidylinositol 3-kinase delta (PI3K) inhibitor | CAL-101 | DELTA | P110-DELTA | PI3K | ONCOLOGY | INHIBITOR | HEMATOLOGY | SUBUNIT | Index Medicus | Reviews | Review
Journal Article
TURKISH JOURNAL OF HEMATOLOGY, ISSN 1300-7777, 03/2019, Volume 36, pp. 15 - 16
Journal Article
CANCER, ISSN 0008-543X, 08/2018, Volume 124, Issue 16, pp. 3455 - 3456
Journal Article
Annals of Gastroenterology, ISSN 1108-7471, 2016, Volume 29, Issue 2, pp. 233 - 235
Idelalisib is an oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, approved by FDA since July 2014 for the treatment of relapsed follicular B-cell... 
Diarrhea | Enterocolitis | Idelalisib | enterocolitis | diarrhea | Case Report
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2016, Volume 59, Issue 19, pp. 9228 - 9242
Aberrant signaling of phosphoinositide 3-kinase δ (PI3Kδ) has been implicated in numerous pathologies including hematological malignancies and rheumatoid... 
B-CELLS | CHEMISTRY, MEDICINAL | PI3K-DELTA | CAL-101 | AUTOIMMUNITY | IDELALISIB | PI3 KINASE | MECHANISMS | ARTHRITIS | CANCER | SELECTIVITY
Journal Article
International Journal of Biochemistry and Cell Biology, ISSN 1357-2725, 11/2019, Volume 116, p. 105615
Although conventional therapeutic approaches have brought remarkable advantages for the treatment of breast cancer (BC), drug-resistance still remains as a... 
Arsenic trioxide (ATO) | Breast cancer | PI3K signaling pathway | BKM120 (Buparlisib) | CAL-101 (Idelalisib)
Journal Article
Blood, ISSN 0006-4971, 12/2018, Volume 132, Issue 23, pp. 2422 - 2424
In this issue of Blood, Flinn et al report the final results of the phase 3 registration trial DUO,(1) which compared the novel PI3K delta,gamma inhibitor... 
HEMATOLOGY | IDELALISIB | CHRONIC LYMPHOCYTIC-LEUKEMIA
Journal Article
British Journal of Haematology, ISSN 0007-1048, 04/2019, Volume 185, Issue 1, pp. 193 - 197
Journal Article
Medecine et Maladies Infectieuses, ISSN 0399-077X, 06/2017, Volume 47, Issue 4, pp. 293 - 296
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 9, pp. 2169 - 2178
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the a-and delta-isoforms. Patients and... 
Malignant lymphoma | Copanlisib | Treatment | PI3K inhibitor | treatment | DLBCL | EFFICACY | NON-HODGKINS-LYMPHOMAS | IBRUTINIB | BAY 80-6946 | INTERNATIONAL WORKSHOP | PI3K-DELTA | ONCOLOGY | copanlisib | MANTLE CELL LYMPHOMA | IDELALISIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | malignant lymphoma | Original | Editor's Choice
Journal Article
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 432 - 434
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.